Objective: To observe the clinical effect of Telitacicept intervention in patients with primary Sjogren's syndrome with renal disease. Methods: A retrospective analysis was performed on 2 patients with renal disease of primary Sjogren's syndrome who were admitted to the Rheumatology and Immunology Department of the Second Hospital of Jilin University from January to December 2023 and who met the diagnostic criteria of "Norms for Diagnosis and Treatment of Primary Sjogren's Syndrome" and were treated with Telitacicept intervention. Result: 1.Case 1 was treated continuous treatment of "hormone + hydroxychloroquine + Telitacicept " regularly for 12 weeks, kidney involvement and inflammatory response indexes decreased, symptoms of dry eyes and dry mouth were relieved, ESSDAI score improved by 44%, ESSPRI score improved by 25%, and the total score of MFI-20 decreased by 3 points; 2. Case 2 was treated with continuous treatment of "mycophenol sodium + Telitacicept " regularly for 4 weeks, and the symptoms of dry mouth and dry eyes were improved, the content of humoral immunoglobulin was reduced, and the inflammatory index was decreased. However, the patient's blood creatinine was repeatedly increased and did not decrease, and medication was stopped after review. ESSDAI score improved by 17%, ESSPRI score improved by 20%, and the total score of MFI-20 decreased by 3 points. Conclusion: Telitacicept has a certain clinical effect in the treatment of kidney disease in patients with primary Sjogren's syndrome, and its therapeutic effect is related to the duration of administration.